OxSonics Co-Founder & CSO Professor Constantin Coussios elected as a Fellow of the Royal Academy of Engineering
Oxford, UK – 30th September 2019 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer announced today that co-founder and Chief Scientific Officer, Professor Constantin Coussios has been elected as a Fellow of the Royal Academy of Engineering.
Professor Constantin Coussios has been elected a Fellow of the Royal Academy of Engineering in recognition of his outstanding and continuing contributions to biomedical engineering. As well as being Professorial Fellow of Engineering Science, Constantin holds the first Statutory Chair in Biomedical Engineering at the University of Oxford, is the Director of the Institute of Biomedical Engineering (IBME), and a co-founder of OxSonics, OrthoSon and OrganOx.
Colin Story, CEO commented: “OxSonics owes its foundation to the ground-breaking developments made at the IBME of which Constantin is Director. This award recognizes Constantin’s tremendous contributions to the field of Biomedical Engineering as a whole and further validates Oxford as a worldwide centre of excellence for therapeutic ultrasound and drug delivery.”
See the following links for more information:
– ENDS –
About OxSonics Therapeutics
OxSonics® Therapeutics’ proprietary platform technology, SonoTran®, is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
The SonoTran drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.
For more information please visit: www.oxsonics.com.
About the Royal Academy of Engineering
We bring together the most successful and talented engineers from across the profession – our Fellows – to advance and promote excellence in engineering for the benefit of society.
We have three strategic priorities: make the UK the leading nation for engineering innovation and businesses, address the engineering skills crisis, and position engineering at the heart of society.
We are a national academy with a global outlook.
For more information please visit www.raeng.org.uk.